Psychiatr. praxi 2017; 18(1): 17-20 | DOI: 10.36290/psy.2017.004

Clozapine in the treatment of bipolar disorder

prof. MUDr. Klára Látalová, Ph.D.
Klinika psychiatrie FN v LF UP v Olomouci

The growing number of studies shows that clozapine is useful in the treatment of mood disorders either with psychotic symptoms

or without psychotic symptoms, and especially in the treatment of resistant bipolar disorder. It has been found that the use of

clozapine in bipolar disorder is significantly associated with a reduced number of psychiatric hospitalization reduction additives

psychotropics and minor pumping health care due to self-harming or overdose. It is highly likely that clozapine has strong mood

stabilizing effects. Clozapine has more than other antipsychotics, specific “anti-aggressive effect” and has sedative effects also.

Antiaggressive effect of clozapine is mediated by multiple paths. The rapid mood stabilizing effect of clozapine is fast, and may

be related to its antiaggressive effect. In addition, anti-aggressive advantages clozapine continue yet months after the acute

phase of treatment.

Keywords: bipolar disorder, tratment, clozapine, mood stabillisers, antipsychotics

Published: May 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Látalová K. Clozapine in the treatment of bipolar disorder. Psychiatr. praxi. 2017;18(1):17-20. doi: 10.36290/psy.2017.004.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Goodwin FK, Jamison KR. Manic Depressive Illness. 2nd ed. New York: Oxford University Press; 2007.
    2. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch. Gen. Psychiatry 2007; 64(5): 543-552. Go to original source... Go to PubMed...
    3. Baldessarini RJ, Salvatore P, Khalsa HM, Gebre-Medhin P, Imaz H, GonzAlez-Pinto A, Perez., et al. Morbidity in 303 first-episode bipolar I disorder patients. Bipolar Disord 2010; 12(3): 264-270. Go to original source... Go to PubMed...
    4. Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden CL. Bipolar depression: overview and commentary. Harv. Rev. Psychiatry. 2010; 18(3): 143-157. Go to original source... Go to PubMed...
    5. Fountoulakis KN, Vieta E, Young A, Yatham L, Grunze H, Blier P, Moeller HJ, Kasper S.The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 4: Unmet Needs in the Treatment of Bipolar Disorder and Recommendations for Future Research. Int J Neuropsychopharmacol. 2016 Oct 11. pii: pyw072. doi: 10.1093/ijnp/pyw072. Go to original source... Go to PubMed...
    6. Pillarella J, Higashi A, Alexander GC, Conti R. Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998-2009. Psychiatr Serv. 2012; 63(1): 83-86. Go to original source... Go to PubMed...
    7. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999; 156: 990-999. Go to original source... Go to PubMed...
    8. McElroy S, Dessain E, Pope H, Jr, Cole J, Keck P, Jr, Frankenberg F, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991; 52: 411-414.
    9. Banov MD, Zarate CA, Jr, Tohen M, Scialabba D, Wines JD, Jr, Kolbrener M, Kim J.W, et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J. Clin. Psychiatry 1994; 55(7): 295-300.
    10. Li XB, Tang YL, Wang CY, de Leon J. Clozapine for treatment-resistant bipolar disorder: a systematic review Bipolar Disord. 2015; 17(3): 235-247. Go to original source... Go to PubMed...
    11. Nielsen J, Kane J, Correll C. Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. Bipolar Disord 2012; 14: 863-869. Go to original source... Go to PubMed...
    12. Chang JS, Ha KS, Young Lee K, Sik Kim Y, Min Ahn Y. The effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders. J. Clin. Psychiatry 2006; 67(3): 461-467. Go to original source... Go to PubMed...
    13. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, et al. S. International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60(1): 82-91. Go to original source... Go to PubMed...
    14. Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr. Res. 2005; 73(2-3): 139-145. Go to original source... Go to PubMed...
    15. Frye MA, Salloum IM. Bipolar disorder and comorbid alcoholism: prevalence rate and treatment considerations. Bipolar Disord. 2006; 8(6): 677-685. Go to original source... Go to PubMed...
    16. Doubek P, Praško J, Masopust J. Bipolární afektivní porucha in Doporučené postupy psychiatrické péče, Psychiatrická společnost ČLS JEP, 2014; 83-96.
    17. Ifteni P, Nielsen J, Burtea V, Correll C, Kane J, Manu P. Effectiveness and safety of rapid clozapine titration in schizophrenia. Acta Psychiatr Scand 2014b; 130: 25-29. Go to original source... Go to PubMed...
    18. Ifteni P, Correll C, Nielsen J, Burtea V, Kane JM, Manu P. Rapid clozapine titration in treatment-refractory bipolar disorder. J Affect Disord 2014a; 166: 168-172. Go to original source... Go to PubMed...
    19. Aksoy Poyraz C, Turan Ş, Demirel ÖF, Usta Sa?lam NG, Y?ld?z N, Duran A. Effectiveness of ultra-rapid dose titration of clozapine for treatment-resistant bipolar mania: case series. Ther Adv Psychopharmacol. 2015; 5(4): 237-242. Go to original source... Go to PubMed...
    20. Stark A, Scott J. A review of the use of clozapine levels to guide treatment and determine cause of death. Aust N Z J Psychiatry 2012; 46: 816-825. Go to original source... Go to PubMed...
    21. Schulte PF, van Dijk D, Cohen D, Bogers J, Bakker B. Comment on 'effectiveness and safety of rapid clozapine titration in schizophrenia'. Acta Psychiatr Scand 2014; 130(1): 69-70. Go to original source... Go to PubMed...
    22. Lee K, Finley P, Alldredge B. Risk of seizures associated with psychotropic medications: emphasis on new drugs and new findings. Expert Opin Drug Saf 2003; 2: 233-247. Go to original source... Go to PubMed...
    23. Varma S, Bishara D, Besag F, Taylor D. Clozapine-related EEG changes and seizures: dose and plasma-level relationships. Ther Adv Psychopharmacol 2011; 1: 47-66. Go to original source... Go to PubMed...
    24. Khan AY, Preskorn SH. Examining concentration-dependent toxicity of clozapine role of therapeutic drug monitoring. J Psychiatr Pract 2005; 11: 289-301. Go to original source... Go to PubMed...
    25. Češková E. Zlepší monitorování krevních hladin adherenci a efekt léčby u schizofrenie? Psychiatr. prax; 2011; 12(4): 167-169.
    26. Merrill D, Dec G, Goff D. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 2005; 25: 32-41. Go to original source... Go to PubMed...
    27. Haas S, Hill R, Krum H, Liew D, Tonkin A, Demos L, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007; 30: 47-57. Go to original source... Go to PubMed...
    28. Frogley C, Taylor D, Dickens G, Picchioni M. A systematic review of the evidence of clozapine's anti-aggressive effects. Int J Neuropsychopharmacol 2012; 15: 1351-1371. Go to original source... Go to PubMed...
    29. Volavka J, Citrome L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int J Clin Pract 2008; 62: 1237-1245. Go to original source... Go to PubMed...
    30. Chengappa K, Vasile J, Levine J, Ulrich R, Baker R, Gopalani A. Clozapine: its impact on aggressive behavior among patients in a state psychiatric hospital. Schizophr Res 2002; 53: 1-6. Go to original source... Go to PubMed...
    31. Bipolar disorder: assessment and management. Dostupné z: https://www.nice.org.uk/guidance/cg185 [online]. [cit. 2016-11-20].
    32. Poo SX, Agius M. Atypical Anti-Psychotics in Adult Bipolar Disorder: Current Evidence and Updates in the NICE guidelines. Psychiatr Danub. 2014; 26(Suppl 1): 322-1329. Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.